These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36871086)

  • 1. Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study.
    Morimoto A; Shioda Y; Kudo K; Kanegane H; Imamura T; Koh K; Kosaka Y; Yuza Y; Nakazawa A; Saito AM; Watanabe T; Nakazawa Y
    Int J Hematol; 2023 Jul; 118(1):107-118. PubMed ID: 36871086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
    Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S;
    Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone.
    Wang W; Ge J; Ma H; Lian H; Cui L; Zhao Y; Li Z; Wang T; Zhang R
    BMC Pediatr; 2024 Jan; 24(1):1. PubMed ID: 38172736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis.
    Cao XX; Duan MH; Zhao AL; Cai H; Chen J; Gao XM; Liu T; Cai HC; Zhang L; Sun J; Liang ZY; Zhou DB; Li J
    Am J Hematol; 2022 Feb; 97(2):203-208. PubMed ID: 34797941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study.
    Morimoto A; Ikushima S; Kinugawa N; Ishii E; Kohdera U; Sako M; Fujimoto J; Bessho F; Horibe K; Tsunematsu Y; Imashuku S;
    Cancer; 2006 Aug; 107(3):613-9. PubMed ID: 16804933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
    Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
    Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan.
    Imamura T; Sato T; Shiota Y; Kanegane H; Kudo K; Nakagawa S; Nakadate H; Tauchi H; Kamizono J; Morimoto A
    Int J Hematol; 2010 May; 91(4):646-51. PubMed ID: 20361277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric langerhans cell histiocytosis: single center experience over a 17-year period.
    İnce D; Demirağ B; Özek G; Erbay A; Ortaç R; Oymak Y; Kamer S; Yaman Y; Kundak S; Vergin C
    Turk J Pediatr; 2016; 58(4):349-355. PubMed ID: 28276205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
    Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
    Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
    [No Abstract]   [Full Text] [Related]  

  • 12. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside.
    Allen CE; Flores R; Rauch R; Dauser R; Murray JC; Puccetti D; Hsu DA; Sondel P; Hetherington M; Goldman S; McClain KL
    Pediatr Blood Cancer; 2010 Mar; 54(3):416-23. PubMed ID: 19908293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapses of multisystem/multifocal bone Langerhans cell histiocytosis in paediatric patients: Data analysis from the JLSG-96/02 study.
    Sakamoto K; Morimoto A; Shioda Y; Imamura T; Imashuku S;
    Br J Haematol; 2023 Mar; 200(6):769-775. PubMed ID: 36511451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of adult Langerhans cell histiocytosis with intensified chemotherapy.
    Minami M; Shima T; Kato K; Yamamoto H; Tsuchihashi K; Oku S; Shimokawa T; Tochigi T; Yoshimoto G; Kamezaki K; Takenaka K; Iwasaki H; Oda Y; Miyamoto T; Akashi K
    Int J Hematol; 2015 Aug; 102(2):244-8. PubMed ID: 25753226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
    Narula G; Pradhan ND; Arora B; Banavali SD
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification.
    Gadner H; Grois N; Pötschger U; Minkov M; Aricò M; Braier J; Broadbent V; Donadieu J; Henter JI; McCarter R; Ladisch S;
    Blood; 2008 Mar; 111(5):2556-62. PubMed ID: 18089850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of 131 children with multi-system Langerhans cell histiocytosis].
    Wu FF; Gao YJ; Pan C; Chen J; Tang JY
    Zhonghua Er Ke Za Zhi; 2016 May; 54(5):349-53. PubMed ID: 27143076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Craniofacial involvement in Langerhans cell histiocytosis: A review of 44 cases at a single medical center.
    Lin TE; Chu YY; Chang TY; Liao HT
    J Plast Reconstr Aesthet Surg; 2023 Jul; 82():12-20. PubMed ID: 37148805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.
    Monsereenusorn C; Suwannaying K; Techavichit P; Sathitsamitphong L; Komvilaisak P; Rujkijyanont P; Seksarn P; Charoenkwan P; Pakakasama S
    Int J Hematol; 2022 Apr; 115(4):563-574. PubMed ID: 35099760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.